JP6389884B2 - 癌を治療するための方法及び組成物 - Google Patents

癌を治療するための方法及び組成物 Download PDF

Info

Publication number
JP6389884B2
JP6389884B2 JP2016526034A JP2016526034A JP6389884B2 JP 6389884 B2 JP6389884 B2 JP 6389884B2 JP 2016526034 A JP2016526034 A JP 2016526034A JP 2016526034 A JP2016526034 A JP 2016526034A JP 6389884 B2 JP6389884 B2 JP 6389884B2
Authority
JP
Japan
Prior art keywords
cells
fli1
group
erg
ews
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016526034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534084A5 (Direct
JP2016534084A (ja
Inventor
トレッツキー,ジェフリー、エー.
ウラン、エイカット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of JP2016534084A publication Critical patent/JP2016534084A/ja
Publication of JP2016534084A5 publication Critical patent/JP2016534084A5/ja
Application granted granted Critical
Publication of JP6389884B2 publication Critical patent/JP6389884B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/38Oxygen atoms in positions 2 and 3, e.g. isatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016526034A 2013-10-24 2014-10-20 癌を治療するための方法及び組成物 Active JP6389884B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361895308P 2013-10-24 2013-10-24
US61/895,308 2013-10-24
PCT/US2014/061418 WO2015061229A1 (en) 2013-10-24 2014-10-20 Methods and compositions for treating cancer

Publications (3)

Publication Number Publication Date
JP2016534084A JP2016534084A (ja) 2016-11-04
JP2016534084A5 JP2016534084A5 (Direct) 2017-11-16
JP6389884B2 true JP6389884B2 (ja) 2018-09-12

Family

ID=52993423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526034A Active JP6389884B2 (ja) 2013-10-24 2014-10-20 癌を治療するための方法及び組成物

Country Status (11)

Country Link
US (2) US9511050B2 (Direct)
EP (1) EP3060207A4 (Direct)
JP (1) JP6389884B2 (Direct)
KR (1) KR20160065986A (Direct)
CN (1) CN105848654B (Direct)
AU (1) AU2014340398A1 (Direct)
CA (1) CA2927148A1 (Direct)
IL (1) IL245281A0 (Direct)
MX (1) MX2016004678A (Direct)
RU (1) RU2016114498A (Direct)
WO (1) WO2015061229A1 (Direct)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232310B2 (en) * 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
EP2350071B1 (en) 2008-10-22 2014-01-08 Array Biopharma, Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PL3205654T3 (pl) 2010-05-20 2019-08-30 Array Biopharma, Inc. Związki makrocykliczne jako inhibitory kinazy TRK
EP2836481B1 (en) 2012-04-12 2018-12-26 Georgetown University Compounds and compositions for treating ewings sarcoma family of tumors
JP6389884B2 (ja) * 2013-10-24 2018-09-12 ジョージタウン・ユニバーシティGeorgetown University 癌を治療するための方法及び組成物
NZ730585A (en) 2014-10-09 2018-08-31 Oncternal Therapeutics Inc Indolinone compounds and uses thereof
CN107428760B (zh) 2014-11-16 2021-04-27 阵列生物制药公司 (s)-n-(5-((r)-2-(2,5-二氟苯基)-吡咯烷-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐的晶型
KR102277538B1 (ko) * 2015-06-08 2021-07-14 주식회사 대웅제약 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물
BR112018008357A2 (en) 2015-10-26 2018-11-27 Loxo Oncology, Inc. dot mutations in trk inhibitor resistant cancer and related methods
EP3795563B1 (en) 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
HRP20201984T1 (hr) 2016-05-18 2021-04-16 Loxo Oncology, Inc. Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
US10613088B2 (en) * 2016-06-12 2020-04-07 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
US10761081B2 (en) * 2016-06-12 2020-09-01 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
MX395539B (es) 2016-07-29 2025-03-25 Oncternal Therapeutics Inc Usos de compuestos de indolinona
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
AU2018229294B2 (en) * 2017-02-28 2024-06-13 Exact Sciences Corporation Detecting prostate cancer
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110845389A (zh) * 2019-10-17 2020-02-28 袁健 一种新型i型拓扑异构酶抑制剂
CN114057626B (zh) * 2021-12-07 2023-06-30 山东第一医科大学(山东省医学科学院) 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物
WO2026009227A1 (en) 2024-07-04 2026-01-08 Yeda Research And Development Co. Ltd. Compositions for downregulating zeb2 in macrophages and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288436C (en) 1983-07-22 1991-09-03 David Paul Hesson Phenylquinolinecarboxylic acids and derivatives as antitumor agents
DE69922997T2 (de) * 1998-12-04 2005-12-15 Neurosearch A/S Verwendung von isatinderivaten als ionenkanalaktivierende mittel
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
EP1750776A2 (en) 2004-04-30 2007-02-14 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a c5-modified pyrimidine
WO2006117414A1 (es) 2005-04-29 2006-11-09 Proyecto De Biomedicina Cima, S.L. Modelo animal no humano de sarcoma
WO2008083326A2 (en) * 2006-12-29 2008-07-10 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
EP2154966B1 (en) 2007-04-20 2013-08-21 The Research Foundation Of State University Of New York Benzimidazoles and pharmaceutical compositions thereof
TW201346030A (zh) 2012-04-02 2013-11-16 Gradalis Inc 依汶氏(EWING’S)肉瘤雙功能shRNA設計
EP2836481B1 (en) 2012-04-12 2018-12-26 Georgetown University Compounds and compositions for treating ewings sarcoma family of tumors
JP6389884B2 (ja) * 2013-10-24 2018-09-12 ジョージタウン・ユニバーシティGeorgetown University 癌を治療するための方法及び組成物

Also Published As

Publication number Publication date
WO2015061229A1 (en) 2015-04-30
US20160263086A1 (en) 2016-09-15
KR20160065986A (ko) 2016-06-09
CA2927148A1 (en) 2015-04-30
EP3060207A1 (en) 2016-08-31
US20170157089A1 (en) 2017-06-08
IL245281A0 (en) 2016-06-30
MX2016004678A (es) 2017-03-10
US9511050B2 (en) 2016-12-06
EP3060207A4 (en) 2017-04-12
JP2016534084A (ja) 2016-11-04
CN105848654A (zh) 2016-08-10
CN105848654B (zh) 2018-10-02
RU2016114498A3 (Direct) 2018-08-13
RU2016114498A (ru) 2017-11-29
AU2014340398A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
JP6389884B2 (ja) 癌を治療するための方法及び組成物
JP6345301B2 (ja) ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物
KR102375929B1 (ko) 인돌린 유사체 및 이의 용도
AU2015328121B2 (en) Indolinone compounds and uses thereof
US11267817B2 (en) Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
Zhao et al. Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
CA3224123A1 (en) Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (jak2)
HK1242313B (zh) 用於治疗尤文肉瘤家族肿瘤的方法和组合物
HK1207368B (en) Compounds and compositions for treating ewings sarcoma family of tumors
HK1242313A1 (en) Methods and compositions for treating ewing's sarcoma family of tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160628

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171003

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180820

R150 Certificate of patent or registration of utility model

Ref document number: 6389884

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250